TY - JOUR
T1 - Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement
T2 - Comparison with EGFR mutation and ALK/EGFR-negative lung cancer
AU - Mori, Mio
AU - Hayashi, Hideyuki
AU - Fukuda, Minoru
AU - Honda, Sumihisa
AU - Kitazaki, Takeshi
AU - Shigematsu, Kazuto
AU - Matsuyama, Naohiro
AU - Otsubo, Mayumi
AU - Nagayasu, Takeshi
AU - Hashisako, Mikiko
AU - Tabata, Kazuhiro
AU - Uetani, Masataka
AU - Ashizawa, Kazuto
N1 - Publisher Copyright:
© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd
PY - 2019/4
Y1 - 2019/4
N2 - Background: The study was conducted to evaluate the clinical and computed tomography (CT) findings of non-small cell lung cancer (NSCLC) patients to distinguish between ALK gene rearrangement, EGFR mutation, and non-ALK/EGFR (no genetic abnormalities). Methods: We enrolled 201 patients with primary NSCLC who had undergone molecular testing for both ALK gene rearrangement and EGFR mutation. The clinical features and CT findings of the main lesion and associated pulmonary abnormalities were investigated. Results: Female gender (P = 0.0043 vs. non-ALK/EGFR), young age (P = 0.0156 vs. EGFR), and a light or never smoking history (P = 0.0039 vs. non-ALK/EGFR) were significant clinical characteristics of NSCLC with ALK gene rearrangement. The significant CT characteristics compared to NSCLC with EGFR mutation were a large mass (P = 0.0155), solid mass (P = 0.0048), and no air bronchogram (P = 0.0148). A central location (P = 0.0322) and lymphadenopathy (P = 0.0353) were also more frequently observed. Coexisting emphysema was significantly less frequent in NSCLC patients with ALK gene rearrangement (P = 0.0135) than non-ALK/EGFR. Conclusions: NSCLC with ALK gene rearrangement was more likely to develop in younger women with a light or never smoking history. The characteristic CT findings of NSCLC with ALK gene rearrangement were a large solid mass, less air bronchogram, a central location, and lymphadenopathy.
AB - Background: The study was conducted to evaluate the clinical and computed tomography (CT) findings of non-small cell lung cancer (NSCLC) patients to distinguish between ALK gene rearrangement, EGFR mutation, and non-ALK/EGFR (no genetic abnormalities). Methods: We enrolled 201 patients with primary NSCLC who had undergone molecular testing for both ALK gene rearrangement and EGFR mutation. The clinical features and CT findings of the main lesion and associated pulmonary abnormalities were investigated. Results: Female gender (P = 0.0043 vs. non-ALK/EGFR), young age (P = 0.0156 vs. EGFR), and a light or never smoking history (P = 0.0039 vs. non-ALK/EGFR) were significant clinical characteristics of NSCLC with ALK gene rearrangement. The significant CT characteristics compared to NSCLC with EGFR mutation were a large mass (P = 0.0155), solid mass (P = 0.0048), and no air bronchogram (P = 0.0148). A central location (P = 0.0322) and lymphadenopathy (P = 0.0353) were also more frequently observed. Coexisting emphysema was significantly less frequent in NSCLC patients with ALK gene rearrangement (P = 0.0135) than non-ALK/EGFR. Conclusions: NSCLC with ALK gene rearrangement was more likely to develop in younger women with a light or never smoking history. The characteristic CT findings of NSCLC with ALK gene rearrangement were a large solid mass, less air bronchogram, a central location, and lymphadenopathy.
UR - http://www.scopus.com/inward/record.url?scp=85062337918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062337918&partnerID=8YFLogxK
U2 - 10.1111/1759-7714.13017
DO - 10.1111/1759-7714.13017
M3 - Article
C2 - 30811109
AN - SCOPUS:85062337918
SN - 1759-7706
VL - 10
SP - 872
EP - 879
JO - Thoracic Cancer
JF - Thoracic Cancer
IS - 4
ER -